145 related articles for article (PubMed ID: 22627626)
1. Evidence of ambiguous differentiation and mTOR pathway dysregulation in subependymal giant cell astrocytoma.
Barrows BD; Rutkowski MJ; Gültekın SH; Parsa AT; Tıhan T
Turk Patoloji Derg; 2012; 28(2):95-103. PubMed ID: 22627626
[TBL] [Abstract][Full Text] [Related]
2. Role of mTOR signaling pathway in the pathogenesis of subependymal giant cell astrocytoma - A study of 28 cases.
Kumari K; Sharma MC; Kakkar A; Malgulwar PB; Pathak P; Suri V; Sarkar C; Chandra SP; Faruq M; Gupta RK; Saran RK
Neurol India; 2016; 64(5):988-94. PubMed ID: 27625244
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
[TBL] [Abstract][Full Text] [Related]
4. Biological behavior and tumorigenesis of subependymal giant cell astrocytomas.
Kim SK; Wang KC; Cho BK; Jung HW; Lee YJ; Chung YS; Lee JY; Park SH; Kim YM; Choe G; Chi JG
J Neurooncol; 2001 May; 52(3):217-25. PubMed ID: 11519851
[TBL] [Abstract][Full Text] [Related]
5. Tuberin and hamartin expression is reduced in the majority of subependymal giant cell astrocytomas in tuberous sclerosis complex consistent with a two-hit model of pathogenesis.
Jóźwiak S; Kwiatkowski D; Kotulska K; Larysz-Brysz M; Lewin-Kowalik J; Grajkowska W; Roszkowski M
J Child Neurol; 2004 Feb; 19(2):102-6. PubMed ID: 15072102
[TBL] [Abstract][Full Text] [Related]
6. Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients.
Kotulska K; Borkowska J; Roszkowski M; Mandera M; Daszkiewicz P; Drabik K; Jurkiewicz E; Larysz-Brysz M; Nowak K; Grajkowska W; Domańska-Pakieła D; Jóźwiak S
Pediatr Neurol; 2014 Apr; 50(4):307-12. PubMed ID: 24507694
[TBL] [Abstract][Full Text] [Related]
7. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb.
Tee AR; Manning BD; Roux PP; Cantley LC; Blenis J
Curr Biol; 2003 Aug; 13(15):1259-68. PubMed ID: 12906785
[TBL] [Abstract][Full Text] [Related]
8. Subependymal giant cell astrocytoma: a lesion with activated mTOR pathway and constant expression of glutamine synthetase.
Buccoliero AM; Caporalini C; Giordano F; Mussa F; Scagnet M; Moscardi S; Baroni G; Genitori L; Taddei GL
Clin Neuropathol; 2016; 35(5):295-301. PubMed ID: 27390104
[TBL] [Abstract][Full Text] [Related]
9. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.
Tee AR; Fingar DC; Manning BD; Kwiatkowski DJ; Cantley LC; Blenis J
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13571-6. PubMed ID: 12271141
[TBL] [Abstract][Full Text] [Related]
10. Subependymal giant cell astrocytoma (SEGA): Is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study.
Buccoliero AM; Franchi A; Castiglione F; Gheri CF; Mussa F; Giordano F; Genitori L; Taddei GL
Neuropathology; 2009 Feb; 29(1):25-30. PubMed ID: 18564101
[TBL] [Abstract][Full Text] [Related]
11. WT1 Clone 6F-H2 Cytoplasmic Expression Differentiates Astrocytic Tumors from Astrogliosis and Associates with Tumor Grade, Histopathology, IDH1 Status, Apoptotic and Proliferative Indices: A Tissue Microarray Study.
Abd El-Hafez A; Ismail Hany HSED
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2403-2413. PubMed ID: 32856872
[TBL] [Abstract][Full Text] [Related]
12. Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin.
Cheng S; Hawkins C; Taylor MD; Bartels U
Pediatr Neurol; 2015 Sep; 53(3):238-242.e1. PubMed ID: 26173783
[TBL] [Abstract][Full Text] [Related]
13. Congenital segmental lymphedema in tuberous sclerosis complex with associated subependymal giant cell astrocytomas treated with Mammalian target of rapamycin inhibitors.
Prato G; Mancardi MM; Baglietto MG; Janis S; Vercellino N; Rossi A; Consales A; Raso A; Garrè ML
J Child Neurol; 2014 Sep; 29(9):NP54-7. PubMed ID: 24056156
[TBL] [Abstract][Full Text] [Related]
14. Tuberous-sclerosis complex-related cell signaling in the pathogenesis of lung cancer.
Fuchs A; König K; Heukamp LC; Fassunke J; Kirfel J; Huss S; Becker AJ; Büttner R; Majores M
Diagn Pathol; 2014 Mar; 9():48. PubMed ID: 24593867
[TBL] [Abstract][Full Text] [Related]
15. WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma.
Rauscher J; Beschorner R; Gierke M; Bisdas S; Braun C; Ebner FH; Schittenhelm J
J Clin Pathol; 2014 Jul; 67(7):556-61. PubMed ID: 24607494
[TBL] [Abstract][Full Text] [Related]
16. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas.
Cryan JB; Haidar S; Ramkissoon LA; Bi WL; Knoff DS; Schultz N; Abedalthagafi M; Brown L; Wen PY; Reardon DA; Dunn IF; Folkerth RD; Santagata S; Lindeman NI; Ligon AH; Beroukhim R; Hornick JL; Alexander BM; Ligon KL; Ramkissoon SH
Oncotarget; 2014 Sep; 5(18):8083-92. PubMed ID: 25257301
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA).
Ebrahimi-Fakhari D; Franz DN
Expert Opin Pharmacother; 2020 Aug; 21(11):1329-1336. PubMed ID: 32338549
[TBL] [Abstract][Full Text] [Related]
18. Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile.
Giannikou K; Zhu Z; Kim J; Winden KD; Tyburczy ME; Marron D; Parker JS; Hebert Z; Bongaarts A; Taing L; Long HW; Pisano WV; Alexandrescu S; Godlewski B; Nellist M; Kotulska K; Jozwiak S; Roszkowski M; Mandera M; Thiele EA; Lidov H; Getz G; Devinsky O; Lawrence MS; Ligon KL; Ellison DW; Sahin M; Aronica E; Meredith DM; Kwiatkowski DJ
Mod Pathol; 2021 Feb; 34(2):264-279. PubMed ID: 33051600
[TBL] [Abstract][Full Text] [Related]
19. The coding and non-coding transcriptional landscape of subependymal giant cell astrocytomas.
Bongaarts A; van Scheppingen J; Korotkov A; Mijnsbergen C; Anink JJ; Jansen FE; Spliet WGM; den Dunnen WFA; Gruber VE; Scholl T; Samueli S; Hainfellner JA; Feucht M; Kotulska K; Jozwiak S; Grajkowska W; Buccoliero AM; Caporalini C; Giordano F; Genitori L; Coras R; Blümcke I; Krsek P; Zamecnik J; Meijer L; Scicluna BP; Schouten-van Meeteren AYN; Mühlebner A; Mills JD; Aronica E
Brain; 2020 Jan; 143(1):131-149. PubMed ID: 31834371
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants.
Joseph NM; Phillips J; Dahiya S; M Felicella M; Tihan T; Brat DJ; Perry A
Mod Pathol; 2013 Mar; 26(3):315-26. PubMed ID: 23041832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]